April W. Armstrong, MD, MPH

Efficacy and Safety of Zasocitinib in Psoriasis and the Ideal Candidates for TYK2 Inhibitors

What are your impressions of the Phase 2b data of zasocitinib in psoriasis, particularly in terms of Psoriasis Area and Severity Index (PASI) responses, dose-dependent effects, and tolerability? 

How do you see these results influencing your real-world patient selection?

Videos


What are your impressions of the Phase 2b data of zasocitinib in psoriasis, particularly in terms of Psoriasis Area and Severity Index (PASI) responses, dose-dependent effects, and tolerability? How do you see these results influencing your real-world patient selection?

Understanding the FDA-Approved TYK2 Inhibitor in Psoriasis

Deucravacitinib, approved in 2022, was the first selective TYK2 inhibitor for moderate-to-severe psoriasis. Can you describe its mechanism of action?


What are your impressions of the recently published long-term data for deucravacitinib in plaque psoriasis, which demonstrated sustained efficacy and a consistent safety profile through five years of treatment?


How does this data influence your perception of its role in long-term disease management?


Which patients are ideal candidates for deucravacitinib?

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Latest Updates in Oral BTKi from Derm Fall Clinical 2025

series focuses on optimizing management for 

 through evidence-based and individualized care. 

, highlighting diagnostic distinctions between spontaneous, inducible, and secondary forms. She emphasizes the importance of structured disease assessment using standardized tools such as the

 to track response and inform timely escalation. The discussion outlines key predictors of poor response to antihistamines and the critical need for proactive, rather than reactive, treatment decisions to prevent chronic disease burden.

The program then explores therapeutic innovation, particularly the rise of 

, which demonstrated rapid, durable symptom control and sustained remission through 52 weeks in the 

 trials. Armstrong examines how these findings may redefine long-term management goals and reshape patient expectations around control vs remission. She provides guidance on communicating treatment transitions, addressing concerns about injectables vs oral therapies, and balancing efficacy with adherence and accessibility—particularly as small molecule therapies expand options beyond traditional biologics such as omalizumab.

Finally, the conversation looks ahead to 

, envisioning a shift from rigid stepwise algorithms to 

. Armstrong discusses emerging biomarkers that could predict treatment response as well as how dermatologists and allergists may increasingly share roles in CSU management as therapeutic categories converge. She closes by highlighting the promise of new oral targeted therapies and the importance of integrating patient-reported outcomes and shared decision-making to achieve lasting control and improved quality of life.

Closing insights on expanding dermatology’s leadership in CSU management and embracing innovation to enhance patient outcomes.

Selectivity of TYK2 Inhibition in Psoriasis

Panelists discuss the questions below in this video.

How does the selectivity of TYK2 inhibition differ from JAK inhibition?


At what level of pathway inhibition (% inhibition of IL-12, IL-23, IFN) do we see efficacy without safety liabilities, and how narrow or wide is this therapeutic window compared to JAK inhibitors?


Loss-of-function TYK2 variants have been linked to protection from psoriasis. How do these genetic findings inform our understanding of TYK2’s role and support selective inhibition as a therapeutic strategy?

Next-generation TIC-2 inhibitors show remarkable selectivity, enhancing efficacy while minimizing side effects, offering insights into immune system safety.

April W. Armstrong, MD, MPH

Articles